Rebecca Day
Family · Corbin, KYNPI 1376941534
Payments from drug & device makers
Across 223 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$735
- Neuronetics, Inc.$365
- Bayer$236
- Johnson & Johnson$218
- Teva Pharmaceuticals USA, Inc.$177
- Amgen$173
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,474100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 72 | $735 |
| Neuronetics, Inc. | 8 | $365 |
| Bayer | 14 | $236 |
| Johnson & Johnson | 11 | $218 |
| Teva Pharmaceuticals USA, Inc. | 11 | $177 |
| Amgen | 8 | $173 |
| Pfizer | 11 | $166 |
| AstraZeneca | 11 | $165 |
| GSK | 10 | $158 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $145 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $114 |
| Alkermes, Inc. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Novo Nordisk | 5 | $78 |
| Braeburn Inc. | 4 | $61 |
| Neurocrine Biosciences, Inc. | 4 | $56 |
| Indivior Inc. | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Astellas Pharma US Inc | 3 | $41 |
| Lilly USA, LLC | 3 | $39 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Gilead | 1 | $28 |
| Bsn Medical Inc | 1 | $27 |
| Lundbeck LLC | 1 | $24 |
| Insulet Corporation | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Merck | 1 | $19 |
| Tolmar, Inc. | 1 | $15 |
| Abbott | 1 | $13 |
| Genentech USA, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,489 in reported general payments places this provider in the 85th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $120,114 |
| Humira PenAdalimumab | 13 | $82,463 |
| FarxigaDapagliflozin Propanediol | 76 | $51,673 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $39,638 |
| Nurtec OdtRimegepant Sulfate | 27 | $38,891 |
| OzempicSemaglutide | 35 | $33,058 |
| LinzessLinaclotide | 53 | $32,039 |
| RexultiBrexpiprazole | 20 | $29,138 |
| EliquisApixaban | 36 | $23,475 |
| TrulicityDulaglutide | 17 | $23,363 |
| JardianceEmpagliflozin | 33 | $22,498 |
| BrixadiBuprenorphine | 15 | $20,823 |
| JanuviaSitagliptin Phosphate | 30 | $18,364 |
| SpravatoEsketamine Hcl | 15 | $17,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $39 | $143,477124 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Nexium | $165 | $102,441149 claims |
| AbbVieLinzess, Qulipta, Ubrelvy, Savella | $735 | $73,09098 claims |
| PfizerNurtec Odt, Eliquis, Abrysvo | $166 | $66,43076 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $158 | $35,46989 claims |
| Novo NordiskOzempic | $78 | $33,05835 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $79 | $29,13820 claims |
| Braeburn Inc.Brixadi | $61 | $20,82315 claims |
| MerckJanuvia | $19 | $18,36430 claims |
| Johnson & JohnsonSpravato | $218 | $17,16515 claims |
| BayerKerendia | $236 | $13,35417 claims |
| Astellas Pharma US IncVeozah | $41 | $12,22819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,374 family providers in Kentucky.
Other family in Corbin
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.